Keyphrases
Metastatic Renal Cell Carcinoma (mRCC)
100%
Targeted Therapy
77%
Metastatic Melanoma
66%
Health Care Costs
66%
Overall Survival
50%
Long-term Survivors
44%
Patient Demographics
40%
Oncological Treatment
33%
Immune Checkpoint Inhibitors
33%
Renal Cancer
33%
Economic Change
33%
Long-term Survival
33%
Indigo
33%
Progression-free
33%
Patient-reported Outcomes
33%
Clear Cell Renal Cell Carcinoma (ccRCC)
33%
Group Studies
33%
Gene Sequencing
33%
Health Economics
33%
Checkpoint Inhibitors
33%
Inhibitor Agent
33%
Five-factor
33%
Biomarker Profile
33%
Targeted Agents
33%
Socioeconomic Costs
33%
Patient's Will
26%
Relative Risk
25%
National Cohort
24%
Confidence Interval
22%
Medicine Costs
22%
Median Overall Survival
19%
Relative Change
16%
Systemic Treatment
16%
Productivity Loss
15%
Pre-immune
13%
Electronic Patient-reported Outcome (ePRO)
13%
Phase II Study
13%
Tumor Tissue
13%
Tyrosine Kinase Inhibitor
11%
Renal Cell Carcinoma
10%
Denmark
9%
Clinical Trials
9%
Productivity Costs
8%
Drug Costs
8%
Procedure Codes
8%
Multivariate Analysis
7%
Treatment Initiation
7%
Online Treatment
7%
Upper Level
7%
Two-period
6%
Medicine and Dentistry
Targeted Therapy
73%
Metastatic Melanoma
66%
Kidney Metastasis
66%
Health Care Cost
66%
Overall Survival
52%
Patient Population
38%
Health Care
38%
Clear Cell Renal Cell Carcinoma
35%
Gene Sequence
33%
Kidney Cancer
33%
Long Term Survival
33%
Immune Checkpoint Inhibitor
33%
Progression Free Survival
33%
Cancer Therapy
33%
Patient-Reported Outcome
33%
Medicine
18%
Neoplasm
16%
Systemic Therapy
16%
Clinical Trial
13%
Quality of Life
11%
Immunotherapy
7%
Patient Registry
5%
Arm
5%
Physician
5%
Response Evaluation Criteria in Solid Tumors
5%
Genetic Analysis
5%
Symptom
5%
Side Effect
5%
Time to Treatment
5%
Disease
5%
Computer Assisted Tomography
5%
Personalized Medicine
5%
Metastatic Carcinoma
5%
Cancer Types
5%
